AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 114.2 |
Market Cap | 4.09B |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | 1.77 |
PE Ratio (ttm) | 80.26 |
Forward PE | n/a |
Analyst | Buy |
Ask | 180.53 |
Volume | 345,818 |
Avg. Volume (20D) | 256,090 |
Open | 152.94 |
Previous Close | 150.31 |
Day's Range | 141.72 - 152.94 |
52-Week Range | 107.50 - 219.34 |
Beta | undefined |
About KRYS
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive con...
Analyst Forecast
According to 7 analyst ratings, the average rating for KRYS stock is "Buy." The 12-month stock price forecast is $212, which is an increase of 49.23% from the latest price.
Next Earnings Release
Analysts project revenue of $95.89M, reflecting a 127.53% YoY growth and earnings per share of 0.96, making a 220.00% increase YoY.